Skip to main content
Premium Trial:

Request an Annual Quote

Cellumen to Develop Drug Toxicity Biomarkers for Mitsubishi Tanabe

NEW YORK (GenomeWeb News) – Cellumen said today that it will help Mitsubishi Tanabe Pharma to develop biomarker panels that could be used to help the company identify drug toxicity early in the drug development process.
Pittsburgh-based Cellumen offers the CellCiphr CSB Toxicity Profiling Service, which is aimed at identifying toxic compounds in late primary screening through the early pre-clinical phases of drug development. The company said the service can help companies find problematic compounds before beginning the “expensive pre-clinical testing where the pharmaceutical industry is losing millions of dollars from drugs that do not meet the FDA's safety requirements.”
The CellCiphr service provides an index of safety risks for compounds that can be used to help scientists predict potential rodent or human toxicity, the company said.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.